For the quarter ending 2025-09-30, KPHMW had $4,480,635 increase in cash & cash equivalents over the period. -$1,273,519 in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net (loss) income | 26,806 | -4,345,439 |
| Depreciation and amortization | 10,552 | 3,741 |
| Research credit receivables | - | 414,288 |
| Impairment of intangible assets | 0 | - |
| Reduction of operating lease right-of-use assets | 27,683 | 47,364 |
| Stock-based compensation | 254,398 | 411,390 |
| In-process r&d impairment | 0 | - |
| Change in fair value of contingent consideration | -1,721,033 | 412,966 |
| Investment income and fair value adjustments on marketable securities and cash equivalents | -41,479 | 34,415 |
| Prepaid expenses and other current assets | -306,938 | -440,532 |
| Collaboration receivables | -1,204,796 | 1,816,825 |
| Tax receivables | 1,172,256 | -17,774 |
| Other assets | -2,885 | 35,502 |
| Accounts payable | -40,564 | 509,579 |
| Accrued expenses | -412,015 | -2,159,538 |
| Accrued collaboration credit | -189,080 | -756,187 |
| Deferred collaboration revenue | 0 | 1,250,000 |
| Operating lease liabilities | -27,965 | -38,785 |
| Net cash (used in) provided by operating activities | -1,273,088 | -6,507,633 |
| Purchase of property and equipment | 431 | 32,195 |
| Purchases of marketable securities | 0 | 8,175,851 |
| Sales of marketable securities | 0 | 305,000 |
| Maturities of marketable securities | 5,741,000 | 11,240,000 |
| Net cash provided by (used in) investing activities | 5,740,569 | 3,336,954 |
| Gross proceeds from private placement | 0 | 0 |
| Issuance costs for private placement | 0 | 0 |
| Exercise of warrants | 0 | 265,359 |
| Proceeds from line of credit | 1,750,000 | 1,000,000 |
| Repayments of line of credit | 1,750,000 | 1,000,000 |
| Net cash provided by financing activities | 0 | 265,359 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 13,154 | 141,725 |
| Net increase in cash, cash equivalents and restricted cash | 4,480,635 | -2,763,595 |
| Cash and cash equivalents at beginning of period | 3,796,379 | - |
| Cash and cash equivalents at end of period | 5,513,419 | - |
KIORA PHARMACEUTICALS INC (KPHMW)
KIORA PHARMACEUTICALS INC (KPHMW)